Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP226524.RAkuy-yqLcbSAGJivrbv60jwdYQKtEgn52YGRVO2Di_sM130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP226524.RAkuy-yqLcbSAGJivrbv60jwdYQKtEgn52YGRVO2Di_sM130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP226524.RAkuy-yqLcbSAGJivrbv60jwdYQKtEgn52YGRVO2Di_sM130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP226524.RAkuy-yqLcbSAGJivrbv60jwdYQKtEgn52YGRVO2Di_sM130_provenance.
- NP226524.RAkuy-yqLcbSAGJivrbv60jwdYQKtEgn52YGRVO2Di_sM130_assertion wasGeneratedBy ECO_0000203 NP226524.RAkuy-yqLcbSAGJivrbv60jwdYQKtEgn52YGRVO2Di_sM130_provenance.
- NP226524.RAkuy-yqLcbSAGJivrbv60jwdYQKtEgn52YGRVO2Di_sM130_assertion wasDerivedFrom befree-20140225 NP226524.RAkuy-yqLcbSAGJivrbv60jwdYQKtEgn52YGRVO2Di_sM130_provenance.
- NP226524.RAkuy-yqLcbSAGJivrbv60jwdYQKtEgn52YGRVO2Di_sM130_assertion SIO_000772 11896121 NP226524.RAkuy-yqLcbSAGJivrbv60jwdYQKtEgn52YGRVO2Di_sM130_provenance.
- NP226524.RAkuy-yqLcbSAGJivrbv60jwdYQKtEgn52YGRVO2Di_sM130_assertion evidence source_evidence_literature NP226524.RAkuy-yqLcbSAGJivrbv60jwdYQKtEgn52YGRVO2Di_sM130_provenance.
- NP226524.RAkuy-yqLcbSAGJivrbv60jwdYQKtEgn52YGRVO2Di_sM130_assertion description "[Four tyrosine kinase inhibitors that have activity against KIT are currently being used in clinical trials, and one, STI571, has recently been approved by the United States Food and Drug Administration for treating patients with chronic myelogenous leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP226524.RAkuy-yqLcbSAGJivrbv60jwdYQKtEgn52YGRVO2Di_sM130_provenance.
- befree-20140225 importedOn "2014-02-25" NP226524.RAkuy-yqLcbSAGJivrbv60jwdYQKtEgn52YGRVO2Di_sM130_provenance.